ScholarIQanswers from OpenAlex & ORCID
Anne Lynn S. Chang
ResearcherPublications, citations & collaboration network
Anne Lynn S. Chang is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Anne Lynn S. Chang have?
ScholarIQindexed works
Anne Lynn S. Chang has 381 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Anne Lynn S. Chang have?
ScholarIQcitation count
Anne Lynn S. Chang has 26,333 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Anne Lynn S. Chang?
ScholarIQh-index
Anne Lynn S. Chang has an h-index of 64 in OpenAlex.
What is the i10-index of Anne Lynn S. Chang?
ScholarIQi10-index
Anne Lynn S. Chang has an i10-index of 160 in OpenAlex.
What is the ORCID of Anne Lynn S. Chang?
ScholarIQorcid
The ORCID for Anne Lynn S. Chang is on the source record.
What is the OpenAlex record for Anne Lynn S. Chang?
ScholarIQopenalex
The OpenAlex for Anne Lynn S. Chang is on the source record.
What are the most-cited papers on Anne Lynn S. Chang?
ScholarIQmost cited works
Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma
Aleksandar Sekulić, Michael R. Migden, Anthony E. Oro, Luc Dirix, Karl D. Lewis, John D. Hainsworth, James Solomon, Simon Yoo, Sarah T. Arron, Philip Friedlander, Ellen S. Marmur, Charles M. Rudin, Anne Lynn S. Chang, Jennifer A. Low, Howard Mackey, Robert L. Yauch, Richard Graham, Josina C. Reddy, Axel Hauschild
Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial
Michael R. Migden, Alexander Guminski, Ralf Gutzmer, Luc Dirix, Karl D. Lewis, P. Combemale, R. M. Herd, Ragini R. Kudchadkar, Uwe Trefzer, Sven Gogov, Céline Pallaud, Tingting Yi, Manisha Mone, Martin Kaatz, Carmen Loquai, Alexander Stratigos, H. J. Schulze, Ruth Plummer, Anne Lynn S. Chang, Frank Cornélis, John T. Lear, Dalila Sellami, Reinhard Dummer
Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial
Alexander Stratigos, Aleksandar Sekulić, Ketty Peris, Oliver Bechter, S. Prey, Martin Kaatz, Karl D. Lewis, Nicole Basset‐Séguin, Anne Lynn S. Chang, Stéphane Dalle, Almudena Fernández Orland, Lisa Licitra, Caroline Robert, Claas Ulrich, Axel Hauschild, Michael R. Migden, Reinhard Dummer, Siyu Li, Suk-Young Yoo, Kosalai Kal Mohan, Ebony Coates, Vladimir Janković, Nathalie Fiaschi, Emmanuel Chiebuka Okoye, Ioannis D. Bassukas, Carmen Loquai, Vincenzo De Giorgi, Zeynep Eroglu, Ralf Gutzmer, Jens Ulrich, Susana Puig, Frank Seebach, Gavin Thurston, David M. Weinreich, George D. Yancopoulos, Israel Lowy, Timothy G. Bowler, Matthew G. Fury
Long‐term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42‐month analysis of the phase II randomized, double‐blind BOLT study
Reinhard Dummer, Alexander D. Guminksi, Ralf Gutzmer, John T. Lear, Karl D. Lewis, Anne Lynn S. Chang, P. Combemale, Luc Dirix, Martin Kaatz, Ragini R. Kudchadkar, Carmen Loquai, Ruth Plummer, H.‐J. Schulze, Alexander Stratigos, Uwe Trefzer, Nicholas Squittieri, Michael R. Migden
Long‐term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30‐month analysis of the randomized phase 2 BOLT study
John T. Lear, Michael R. Migden, Karl D. Lewis, Anne Lynn S. Chang, Alexander Guminski, Ralf Gutzmer, Luc Dirix, P. Combemale, Alexander Stratigos, Ruth Plummer, Henry Castro, Tingting Yi, Manisha Mone, J ZHOU, Uwe Trefzer, Martin Kaatz, Carmen Loquai, Ragini R. Kudchadkar, Dalila Sellami, Reinhard Dummer